Ophthalmology Drugs Market is Forecast to Grow at $26 billion in 2022 Ophthalmology Drugs Market is Forecast to 2022 | Page 2

in particular Eylea, Lucentis, Lumigan and Restasis. The report focuses on five key indications
within ophthalmology: glaucoma, age-related macular degeneration (AMD), diabetic macular
edema, diabetic retinopathy and dry eye syndrome. There are currently no therapeutic options
available for the treatment of dry AMD, increasing the need for extensive R&D within this area.
Although there is a high degree of failure and uncertainty within the R&D of ophthalmology drugs,
the number of drugs in the pipeline is very high, at 734. The majority of pipeline products are
novel active pharmaceutical ingredients, with only a small proportion of products being either
generics or repositioned from other indications. This shows progression in terms of the variety of
different molecules being developed as therapeutic agents within the ophthalmology pipeline. The
expected growth of the ophthalmology market over the forecast period is attributed to the approval
of new drugs, as well as rising prevalence.
Related reports by Radiant Insights:
http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare
Scope
- Global revenues for the ophthalmology market are forecast to grow at a compound annual growth
rate of 9.48%, from $13.7 billion in 2015 to $26 billion in 2022. Which drugs will achieve
blockbuster status and how will the key player companies perform during the forecast period?
- The ophthalmology pipeline is large and diverse, and contains 734 products. How does the
composition of the pipeline compare with that of the existing market?
- What mechanisms of action and molecule types are most commonly being trialed in pipeline
products in the various key indications?
- Which products will contribute to market growth most significantly, and which will achieve
blockbuster status?
- Will the current market leaders retain their dominance over the forecast period, and how is their
revenue share of the dermatology market set to change?
Reasons to buy
This report will allow you to -
- Understand the current clinical and commercial landscape by considering disease pathogenesis,
diagnosis, prognosis, and the treatment options available at each stage of diagnosis
- Visualize the composition of the ophthalmology market across each indication, in terms of
dominant molecule types and targets, highlighting the key commercial assets and players
Follow Us: